BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 32497036)

  • 1. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice.
    Kim O; Park EY; Klinkebiel DL; Pack SD; Shin YH; Abdullaev Z; Emerson RE; Coffey DM; Kwon SY; Creighton CJ; Kwon S; Chang EC; Chiang T; Yatsenko AN; Chien J; Cheon DJ; Yang-Hartwich Y; Nakshatri H; Nephew KP; Behringer RR; Fernández FM; Cho CH; Vanderhyden B; Drapkin R; Bast RC; Miller KD; Karpf AR; Kim J
    PLoS Genet; 2020 Jun; 16(6):e1008808. PubMed ID: 32497036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice.
    Kim J; Coffey DM; Ma L; Matzuk MM
    Endocrinology; 2015 Jun; 156(6):1975-81. PubMed ID: 25815421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer.
    Yu Z; Kim J; He L; Creighton CJ; Gunaratne PH; Hawkins SM; Matzuk MM
    Biol Reprod; 2014 Nov; 91(5):113. PubMed ID: 25273528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-grade serous ovarian cancer arises from fallopian tube in a mouse model.
    Kim J; Coffey DM; Creighton CJ; Yu Z; Hawkins SM; Matzuk MM
    Proc Natl Acad Sci U S A; 2012 Mar; 109(10):3921-6. PubMed ID: 22331912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
    Modi DA; Tagare RD; Karthikeyan S; Russo A; Dean M; Davis DA; Lantvit DD; Burdette JE
    Oncogene; 2017 May; 36(21):3015-3024. PubMed ID: 27991925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.
    Walton JB; Farquharson M; Mason S; Port J; Kruspig B; Dowson S; Stevenson D; Murphy D; Matzuk M; Kim J; Coffelt S; Blyth K; McNeish IA
    Sci Rep; 2017 Dec; 7(1):16827. PubMed ID: 29203787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
    McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR
    Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 10. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
    Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N
    J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern.
    Kim HN; Woo HY; DO SI; Kim HS
    In Vivo; 2019; 33(5):1485-1492. PubMed ID: 31471396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of TRP53, PTEN, RB1, and/or CDH1 in the ovarian surface epithelium induces ovarian cancer transformation and metastasis.
    Shi M; Whorton AE; Sekulovski N; Paquet M; MacLean JA; Song Y; Van Dyke T; Hayashi K
    Biol Reprod; 2020 Apr; 102(5):1055-1064. PubMed ID: 31930396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell Origins of High-Grade Serous Ovarian Cancer.
    Kim J; Park EY; Kim O; Schilder JM; Coffey DM; Cho CH; Bast RC
    Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30424539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired
    Nesic K; Kondrashova O; Hurley RM; McGehee CD; Vandenberg CJ; Ho GY; Lieschke E; Dall G; Bound N; Shield-Artin K; Radke M; Musafer A; Chai ZQ; Ghamsari MRE; Harrell MI; Kee D; Olesen I; McNally O; Traficante N; Australian Ovarian Cancer Study ; DeFazio A; Bowtell DDL; Swisher EM; Weroha SJ; Nones K; Waddell N; Kaufmann SH; Dobrovic A; Wakefield MJ; Scott CL
    Cancer Res; 2021 Sep; 81(18):4709-4722. PubMed ID: 34321239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
    Morency E; Leitao MM; Soslow RA
    Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific Mechanisms of Chromosomal Instability Indicate Therapeutic Sensitivities in High-Grade Serous Ovarian Carcinoma.
    Tamura N; Shaikh N; Muliaditan D; Soliman TN; McGuinness JR; Maniati E; Moralli D; Durin MA; Green CM; Balkwill FR; Wang J; Curtius K; McClelland SE
    Cancer Res; 2020 Nov; 80(22):4946-4959. PubMed ID: 32998996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel, genetically induced mouse model that recapitulates the histological morphology and immunosuppressive tumor microenvironment of metastatic peritoneal carcinomatosis.
    Tseng SH; Park ST; Lam B; Tsai YC; Cheng MA; Farmer E; Xing D; Hung CF
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32111730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of mesothelial genes in ovarian carcinoma cells is associated with an unfavorable clinical outcome and the promotion of cancer cell adhesion.
    Ojasalu K; Brehm C; Hartung K; Nischak M; Finkernagel F; Rexin P; Nist A; Pavlakis E; Stiewe T; Jansen JM; Wagner U; Gattenlöhner S; Bräuninger A; Müller-Brüsselbach S; Reinartz S; Müller R
    Mol Oncol; 2020 Sep; 14(9):2142-2162. PubMed ID: 32533757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    Škapa P; Dundr P
    Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.